RWE, Market Access, Pricing & Reimbursement Global Congress 2022 Europe

Days
Hours
Minutes
Seconds

1st - 2nd March 2022 - 2 Day Conference
London, UK

Venue

Hilton London Kensington, London, UK

Address

179-199 Holland Park Ave, London W11 4UL, UK

Phone

+44 (0) 207 193 3485

RWE, Market Access, Pricing & Reimbursement

Global Congress 2022 Europe

On a global scale, the pharmaceutical market is expected to grow in the years to come regardless of the recent slowdown in key markets across the globe. The increase is exacerbated by the growing and ageing population in key markets. Aside from this, increasing access to Pharmaceuticals to poor and middle-class families due to increases in disposable income also driving the growth of the industry. Pharma companies focusing on Rare and specialty medicines is another aspect leading the growth. Innovations attracting investments even from non-pharma companies are also sustaining the growth in the pharmaceutical industry.

The pharmaceutical industry is one of the major players in the healthcare sector. Governments across Europe are struggling to balance the desire to provide timely access to innovative medicines with the need to contain healthcare spending due to the increasing pressure between the demands of the EU, national governments, and regional authorities.

Co-located with

The 8th RWE, Market Access, Pricing & Reimbursement 2022 Europe, will be Co-located Expanded Access Programmes Global Congress 2022 Europe.  

Joint Networking at the Exhibit area.

Take advantage of networking with attendees and participants with receptive mindsets, from both events.

To find out about the range of branding, Exhibit, and Sponsorship Options, get in touch. 

Scroll to Top

Dear Colleagues,

On a global scale, the pharmaceutical market is expected to grow in the years to come regardless of a recent slowdown in key markets across the globe. The increase is exacerbated by the growing and ageing population in key markets. Aside from this, increasing access to Pharmaceuticals to poor and middle-class families due to increases in disposable income also drives the industry’s growth. Pharma companies focusing on Rare and speciality medicines is another aspect leading the growth. Innovations attracting investments even from non-pharma companies are also sustaining the growth in the pharmaceutical industry.

The pharmaceutical industry is one of the major players in the healthcare sector. Payers want to provide access and fund innovative treatments to improve patient care but governments across Europe are struggling to balance the desire to provide timely access to innovative medicines with the need to contain healthcare spending due to the increasing pressure between the demands of the EU, national governments and regional authorities.

As healthcare budgets are continuously rising in Europe, governments implement a wide variety of policies to control them with the help of different public regulatory bodies that are involved in pharmaceutical coverage decisions across Europe. International collaboration among HTA and regulatory bodies can promote knowledge exchange, as do the actions payers take in an effort to reduce costs while maintaining quality care.

The upcoming 2022 RWE, Market Access, Pricing and Reimbursement Global Congress Europe will present a dynamic approach to key trends and insights on market access, health
technology assessment, real-world data, patient access, pricing and reimbursement on the current European landscape.

This year, we are putting together an agenda that addresses “A New Model of Access Strategy for the Next Normal.”. We are gathering together high calibre expert speakers to participate and share their knowledge and expertise through Keynote Presentations and Panel discussions, addressing all aspects of the industry.

We look forward to welcoming you to the RWE, MAPR 2022 congress!

Sincerely yours,

Jocelyn Raguindin
Jocelyn Raguindin

Jocelyn is Conference Director at Paradigm Global Events (PGE). She has over 15+ years experience in organizing pharma-industry conferences and has been at the helm of every PGE conference since 2013. Jocelyn is based in London, UK.

Why you should attend:

You Will Meet:

Network with members of boards, VP’s, Directors, Heads/Chiefs and Senior Managers of leading biopharmaceutical and biotech companies, government, CRO and solution providers involved in:

Thilo Schaufler

Head of Market Access Nephrology, Vifor Pharma

Dr. Thilo Schaufler, Head of Market Access Nephrology, Vifor Pharma

Thilo Schaufler is a seasoned professional with 15 years’ experience in market access and health policy roles, providing strategic leadership to global and local cross-functional teams to support business growth. He has co-led successful product launches, indication expansions as well as the loss of exclusivity of major assets.

Since 2018, he is responsible for Market Access for Vifor’s global nephrology portfolio. Before that, he held roles of increasing responsibility at Roche, AbbVie, Amgen, and Pfizer. Thilo holds a doctorate in health economics from the University of Mannheim and a dual degree in political sciences and economics.

Monika Szkultecka - Debek

Vice president of Qualitas Vitae Institute Foundation.

Monika Szkultecka – Debek, MD, PhD, Vice president of Qualitas Vitae Institute Foundation.

Monika Szkultecka – Debek, MD, PhD has medical education and is post graduate in Health Economics.
With over twenty years of experience in the pharmaceutical industry initially she focused her work on clinical research, and then on market access, specifically on activities related to HTA, health economics and outcomes research, Quality of Life and real world data. Contributed to a number of international conferences as speaker, organized and delivered international training on HTA, RWD and QoL. Cooperated with Warsaw University (reviews of master’s theses focused on HTA) and with Koźminski University in Warsaw (workshops at Health Economics and Big Data Master Studies).

Author and co-author of numerous scientific publications related to QoL, RWD and HTA, books, e.g. QoL English – Polish Dictionary, Polish ISPOR Chapter Pricing and Reimbursement Dictionary, Polish QoL Lexicon, chapters in students books related to: QoL and RWD, book chapter about use of RWD in pharmacoeconomics. She has a long history as a reviewer in several specialist journals. Member of the Editorial Advisory Board of the Journal of Health Policy and Outcomes Research (JHPOR) and from 2017 until present Deputy Editor in Chief of JHPOR.
Since April 2021 Vice president of Qualitas Vitae Institute Foundation.

Dr. Marco Rauland

VP, Global Market Access & Pricing - Strategic Planning, Merck KGaA

Marco Rauland has more than 25 years of drug development, marketing, market research and pricing consulting experience in the pharmaceutical industry. Prior to joining Merck, Marco was Vice President Europe of GfK’s Market Access practice. Before that Marco was the global head of the pricing, access and reimbursement practice of Genactis and Senior director of the pricing and reimbursement business unit at TNS Healthcare (now Kantar Group).

Marco is an expert in global pricing, listing and reimbursement strategy and has extensive experience in implementing pricing, access and reimbursement solutions at all stages of the product life cycle, from early product development to post-launch pricing strategies. He has developed the pricing, access and reimbursement strategy for product launches across numerous therapy areas and has in-depth knowledge of international country pricing & reimbursement systems. Marco studied Biochemistry and Pharmacology at the University of Cologne and holds a PhD in Natural Science.

Marta Parmar

Executive Director, International Regulatory Affairs, Alexion Pharma GmbH

Marta Parmar is the Head of International Regulatory Affairs at Alexion. Dr Parmar has over 18 years of combined R&D and regulatory strategy experience. She joined Alexion, AstraZeneca Rare Disease, in 2019 and has taken the role of Lead for the International Region shaping the regulatory environment for medicines under development for rare diseases in markets outside of the US and Japan. She received her PhD in Molecular Biology from the University of Zürich where she is currently based.